Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Ann Surg Oncol. 2018 Feb;25(2):520-527. doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.
The 7th AJCC T-stage system for adrenocortical carcinoma (ACC), based on size and extra-adrenal invasion, does not adequately stratify patients by survival. Lymphovascular invasion (LVI) is a known poor prognostic factor. We propose a novel T-stage system that incorporates LVI to better risk-stratify patients undergoing resection for ACC.
Patients undergoing curative-intent resections for ACC from 1993 to 2014 at 13 institutions comprising the US ACC Group were included. Primary outcome was disease-specific survival (DSS).
Of the 265 patients with ACC, 149 were included for analysis. The current T-stage system failed to differentiate patients with T2 versus T3 disease (p = 0.10). Presence of LVI was associated with worse DSS versus no LVI (36 mo vs. 168 mo; p = 0.001). After accounting for the individual components of the current T-stage system (size, extra-adrenal invasion), LVI remained a poor prognostic factor on multivariable analysis (hazard ratio 2.14, 95% confidence interval 1.05-4.38, p = 0.04). LVI positivity further stratified patients with T2 and T3 disease (T2: 37 mo vs. median not reached; T3: 36 mo vs. 96 mo; p = 0.03) but did not influence survival in patients with T1 or T4 disease. By incorporating LVI, a new T-stage classification system was created: [T1: ≤ 5 cm, (-)local invasion, (+/-)LVI; T2: > 5 cm, (-)local invasion, (-)LVI OR any size, (+)local invasion, (-)LVI; T3: > 5 cm, (-)local invasion, (+)LVI OR any size, (+)local invasion, (+)LVI; T4: any size, (+)adjacent organ invasion, (+/-)LVI]. Each progressive new T-stage group was associated with worse median DSS (T1: 167 mo; T2: 96 mo; T3: 37 mo; T4: 15 mo; p < 0.001).
Compared with the current T-stage system, the proposed T-stage system, which incorporates LVI, better differentiates T2 and T3 disease and accurately stratifies patients by disease-specific survival. If externally validated, this T-stage classification should be considered for future AJCC staging systems.
基于大小和肾上腺外侵犯的第 7 版 AJCC T 分期系统不能充分根据生存情况对肾上腺皮质癌 (ACC) 患者进行分层。淋巴管侵犯 (LVI) 是已知的不良预后因素。我们提出了一种新的 T 分期系统,该系统将 LVI 纳入其中,以更好地对接受 ACC 切除术的患者进行风险分层。
纳入了 1993 年至 2014 年在美国 ACC 小组 13 个机构接受根治性切除术的 ACC 患者。主要结局是疾病特异性生存 (DSS)。
在 265 例 ACC 患者中,有 149 例进行了分析。当前的 T 分期系统无法区分 T2 与 T3 期疾病 (p=0.10)。存在 LVI 与无 LVI 相比,DSS 更差 (36 个月 vs. 168 个月;p=0.001)。在考虑当前 T 分期系统的各个组成部分 (大小、肾上腺外侵犯) 后,LVI 在多变量分析中仍然是一个不良预后因素 (风险比 2.14,95%置信区间 1.05-4.38,p=0.04)。LVI 阳性进一步分层了 T2 和 T3 期疾病患者 (T2:37 个月 vs. 中位数未达到;T3:36 个月 vs. 96 个月;p=0.03),但对 T1 或 T4 期疾病患者的生存无影响。通过纳入 LVI,创建了一个新的 T 分期分类系统:[T1:≤5cm,(-)局部侵犯,(+)/-LVI;T2:>5cm,(-)局部侵犯,(-)LVI 或任何大小,(+)局部侵犯,(-)LVI;T3:>5cm,(-)局部侵犯,(+)LVI 或任何大小,(+)局部侵犯,(+)LVI;T4:任何大小,(+)邻近器官侵犯,(+)/-LVI]。每个新的 T 分期组的中位 DSS 均较差 (T1:167 个月;T2:96 个月;T3:37 个月;T4:15 个月;p<0.001)。
与当前的 T 分期系统相比,新提出的 T 分期系统将 LVI 纳入其中,可更好地区分 T2 和 T3 期疾病,并准确根据疾病特异性生存情况对患者进行分层。如果外部验证成功,该 T 分期分类系统应考虑纳入未来的 AJCC 分期系统。